// App-Quantinova.ai

333P : CIRCULATING TUMOR CELL COUNT AT BASELINE IS AN INDEPENDENT PROGNOSTIC FACTOR FROM PATHOLOGICAL COMPLETE RESPONSE AMONG PATIENTS TREATED FOR PRIMARY INFLAMMATORY HER2-POSITIVE BREAST CANCER: SURVIVAL RESULTS OF THE BEVERLY-2 STUDY

Researchers

Presenter

  • J. Pierga

Principal Investigators

  • T. Petit

  • C. Levy

  • M. Coudert

  • J. Hernandez

  • F.C. Bidard

  • P. Viens

  • J. Ferrero

  • M. Campone

  • J. Gligorov

  • F. Lerebours

  • H. Roche

  • T. Bachelot

  • E. Charafe-Jauffret

  • J. Bonneterre

Medical Centers

  • Oncology Department, Institut Curie, Paris, France

  • Medical Oncology, Centre Leon Berard, Lyon, France

Locations

  • France

Companies

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved